(CercleFinance.com) – Roche announced Tuesday that the US FDA had granted priority review to Xolair for the prevention of food allergies in children and adults.
If given the green light by the health authority, Xolair would become the first drug approved to reduce allergic reactions in the event of accidental exposure of patients.
According to the first results of a phase III clinical study, Xolair significantly reduced the quantity of peanuts, milk, eggs or cashews necessary to trigger an allergic reaction in the individuals monitored.
According to the laboratory, some 17 million Americans currently suffer from food allergies, including more than 40% of children and 50% of adults who have already had to deal with a severe reaction or more.
The FDA’s decision is expected during the first quarter of 2024.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
